Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K. Furst DE, et al. Among authors: bresnihan b. Ann Rheum Dis. 2010 Jan;69 Suppl 1:i2-29. doi: 10.1136/ard.2009.123885. Ann Rheum Dis. 2010. PMID: 19995740 No abstract available.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH. Furst DE, et al. Among authors: bresnihan b. Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834. Ann Rheum Dis. 2008. PMID: 19022808 No abstract available.
Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds.
Silman A, Klareskog L, Breedveld F, Bresnihan B, Maini R, Van Riel P, Symmons D. Silman A, et al. Among authors: bresnihan b. Ann Rheum Dis. 2000 Jun;59(6):419-20. doi: 10.1136/ard.59.6.419. Ann Rheum Dis. 2000. PMID: 10834856 Free PMC article. No abstract available.
Imaging in rheumatoid arthritis: results of group discussions.
Molenaar ET, Boers M, van der Heijde DM, Alarcón G, Bresnihan B, Cardiel M, Edmonds J, Felson D, Furst DE, Kirwan J, Lassere M, Paulus H, Rau R, van Riel PL, Scott D, Simon L, Strand V. Molenaar ET, et al. Among authors: bresnihan b. J Rheumatol. 1999 Mar;26(3):749-51. J Rheumatol. 1999. PMID: 10090196
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP. Haringman JJ, et al. Among authors: bresnihan b. Arthritis Rheum. 2006 Aug;54(8):2387-92. doi: 10.1002/art.21975. Arthritis Rheum. 2006. PMID: 16869001 Free article. Clinical Trial.
Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
Vandooren B, Cantaert T, van Lierop MJ, Bos E, De Rycke L, Veys EM, De Keyser F, Bresnihan B, Luyten FP, Verdonk PC, Tak PP, Boots AH, Baeten D. Vandooren B, et al. Among authors: bresnihan b. Ann Rheum Dis. 2009 Jun;68(6):1044-50. doi: 10.1136/ard.2007.085837. Epub 2008 Jul 16. Ann Rheum Dis. 2009. PMID: 18633128
254 results